Ataxia-Telangiectasia (AT)

Table of Contents

  1. What is Ataxia-Telangiectasia?
  2. The ATM Gene: Master Regulator of DNA Repair
  3. Cerebellar Ataxia: Neurological Decline
  4. Telangiectasias: The Diagnostic Hallmark
  5. Immunodeficiency in AT
  6. Cancer Susceptibility and Radiation Sensitivity
  7. Alpha-Fetoprotein and Diagnosis
  8. Treatment and Supportive Care
  9. Heterozygous ATM Carriers: Family Risk
  10. Living with AT: Practical Guidance
  11. Key Research Papers
  12. Connections
  13. Featured Videos

What is Ataxia-Telangiectasia?

Ataxia-Telangiectasia (AT), also known as Louis-Bar Syndrome, is a rare inherited disease that damages the nervous system, weakens the immune system, and dramatically raises the risk of cancer — all because of a single broken gene. It is one of the most complex multi-system diseases in medicine, touching neurology, immunology, and oncology simultaneously. Understanding AT requires understanding what that one gene normally does and what happens to the body when it stops working.

AT is inherited in an autosomal recessive pattern, meaning a child must inherit two defective copies of the ATM gene — one from each parent — to develop the disease. Parents who each carry one defective copy are healthy carriers and typically have no idea they carry the mutation until an affected child is born. The gene responsible sits on chromosome 11q22.3. AT affects approximately 1 in 40,000 to 100,000 live births worldwide. It strikes boys and girls equally, and its effects begin in early childhood, typically becoming apparent in the first two years of life when a child starts to walk.

The name describes its two most visible features: ataxia (loss of muscle coordination and balance) and telangiectasias (clusters of permanently dilated, spider-like blood vessels visible in the eyes and skin). But these visible signs are only part of the picture. Beneath them, AT causes profound DNA repair failure that silently accumulates damage in neurons, immune cells, and throughout the body — creating the conditions for both progressive neurological decline and markedly elevated cancer risk.

Despite its severity, AT is frequently misdiagnosed in the early years as cerebral palsy, multiple sclerosis, or a simple coordination problem. Recognizing the full pattern — particularly the combination of progressive ataxia, recurrent infections, and elevated alpha-fetoprotein — is essential for early diagnosis and appropriate management.

Back to Table of Contents

The ATM Gene: Master Regulator of DNA Repair

The ATM gene encodes a large protein called ATM kinase — a serine-threonine kinase that serves as the master regulator of the cellular response to DNA double-strand breaks (DSBs). A DNA double-strand break is one of the most dangerous forms of genetic damage: both strands of the DNA helix are severed simultaneously, and if the break is not repaired correctly, the result is chromosomal rearrangements, mutations, or cell death.

When a double-strand break occurs in a healthy cell, ATM is one of the first proteins activated. It works by phosphorylating — chemically tagging — a cascade of downstream proteins that coordinate the cell's response:

Without functional ATM, this entire coordinated response fails. Cells with double-strand breaks continue dividing before their DNA is repaired. Damage accumulates with each cell cycle. Over time, three consequences emerge: neurons die (Purkinje cells in the cerebellum are especially vulnerable), immune cells malfunction (T- and B-cell development requires DNA rearrangements that ATM normally supervises), and cancer develops (accumulated chromosomal instability and failed apoptosis allow malignant cells to proliferate unchecked).

The ATM protein is also critical during the process of V(D)J recombination — the DNA rearrangement that immune cells use to generate the enormous diversity of T-cell receptors and B-cell antibodies. This process requires deliberately cutting and rejoining DNA strands. Without ATM, these programmed cuts are misrepaired, explaining why chromosomal instability in AT is particularly concentrated at the sites of T-cell receptor (chromosomes 7 and 14) and immunoglobulin genes.

Back to Table of Contents

Cerebellar Ataxia: Neurological Decline

The neurological component of AT is typically the first sign that something is wrong. Most children with AT appear to develop normally through infancy, but as they begin to walk — usually around ages 1–2 — parents and clinicians notice that their balance is off. The walk is unsteady, lurching, or wide-based. This is cerebellar ataxia: loss of coordination caused by the progressive death of neurons in the cerebellum, the brain region responsible for fine motor control, balance, and smooth movement coordination.

Cerebellar Purkinje Cell Loss

The neurons most severely affected are Purkinje cells — the large, elaborate neurons that are the primary output cells of the cerebellar cortex. Purkinje cells are exquisitely sensitive to DNA damage because they do not regenerate. Once lost, they are gone permanently. In AT, the failure of ATM to repair DNA double-strand breaks leads to progressive Purkinje cell death throughout childhood and adolescence. As Purkinje cells disappear, the cerebellum loses its ability to fine-tune movement signals, producing progressively worsening ataxia.

Progression Over Time

The trajectory of neurological decline is predictable but varies in pace among individuals. Early in childhood, ataxia may be subtle enough that it is dismissed as normal toddler clumsiness. By school age, the unsteady gait is unmistakable. Most children with AT require a wheelchair by ages 10 to 15 as their legs lose the coordination needed for safe walking. Upper-limb coordination deteriorates in parallel, making tasks like writing, eating, and self-care progressively harder.

Other Neurological Features

Beyond gait ataxia, AT produces several characteristic neurological signs:

Back to Table of Contents

Telangiectasias: The Diagnostic Hallmark

The second part of the name — telangiectasia — refers to permanently dilated, spider-like clusters of small blood vessels that become visible through the skin and in the whites of the eyes. In AT, these appear most characteristically in the conjunctivae (the whites of the eyes), where they can be seen by any physician looking carefully with a light. They also appear on sun-exposed skin: the ears (particularly the helices), the back of the neck, the inner elbows (antecubital fossae), and the nose.

When Telangiectasias Appear

Telangiectasias typically emerge between ages 5 and 8 — notably after ataxia is already well-established. This timing means they are not useful for early diagnosis; by the time a child develops visible conjunctival telangiectasias, the neurological disease is already several years in. Their appearance does, however, clinch the diagnosis when it was previously uncertain.

The Pathognomonic Conjunctival Finding

Conjunctival telangiectasias in AT are considered pathognomonic — meaning their presence is so characteristic of AT that their appearance, combined with ataxia, is essentially diagnostic. They appear as reddish, spidery vessel networks at the limbal junction (where the white sclera meets the colored iris), spreading outward onto the sclera. They are not painful and do not affect vision, but they are unmistakable to an observer familiar with AT.

Telangiectasias do not affect organ function directly but serve as a permanent visual marker of the underlying vascular dysregulation that is part of AT's systemic biology. In the skin, they may become cosmetically bothersome but cause no medical harm. The dangerous manifestations of AT are the neurological, immunological, and oncological — not the vascular ones.

Back to Table of Contents

Immunodeficiency in AT

AT causes a combined T- and B-cell immunodeficiency — meaning both arms of the adaptive immune system are impaired. The severity varies considerably among patients; some have near-normal immune function while others have profound deficiencies. This variability makes AT immunology more nuanced than the immunodeficiency seen in conditions like SCID or XLA.

Why the Immune System Fails in AT

The immune dysfunction in AT stems directly from the ATM gene's role in supervising the DNA rearrangements that immune cells need. Both T-cell receptor (TCR) and immunoglobulin (Ig) gene assembly require V(D)J recombination — a process of precisely cutting and rejoining DNA segments to generate immune diversity. ATM normally monitors these cuts and ensures they are repaired correctly. Without ATM, the rearrangements are error-prone, many immune cell precursors fail to survive development, and the resulting immune cell populations are numerically reduced and functionally impaired.

Thymic Hypoplasia and T-Cell Deficiency

The thymus — the organ where T cells mature — is hypoplastic (underdeveloped) in AT. This results in reduced numbers of circulating T cells, including both helper T cells (CD4+) and cytotoxic T cells (CD8+). Regulatory T-cell function may also be abnormal. The practical consequence is impaired cell-mediated immunity — reduced ability to fight viral infections and certain intracellular bacteria.

Antibody Deficiencies

B-cell function is also impaired. The most common finding is selective IgA deficiency, present in approximately 60% of AT patients — the same percentage seen in the general primary immunodeficiency population, but here it is part of a broader pattern rather than an isolated finding. IgE levels are also frequently low or undetectable. IgG subclass deficiencies are common, particularly IgG2 and IgG4, which are the subclasses responsible for responses to polysaccharide antigens. Total IgG may be normal or mildly reduced. The net effect is poor antibody responses to encapsulated bacteria.

Recurrent Sinopulmonary Infections

The clinical consequence of AT immunodeficiency is recurrent sinopulmonary infections — recurring sinusitis, otitis media (ear infections), bronchitis, and pneumonia. The responsible organisms are the same encapsulated bacteria that cause recurrent infections in other antibody deficiencies: Streptococcus pneumoniae and Haemophilus influenzae. Over years, repeated pulmonary infections drive the development of bronchiectasis — permanent scarring and dilation of the airways — which becomes a major source of respiratory morbidity alongside the neurological decline.

Back to Table of Contents

Cancer Susceptibility and Radiation Sensitivity

AT carries one of the highest cancer risks of any inherited disease. The risk is not incidental — it is a direct and unavoidable consequence of ATM's role as the guardian of the genome. Without ATM to repair double-strand breaks and trigger apoptosis in severely damaged cells, mutations accumulate, chromosomal rearrangements propagate, and malignant clones emerge.

Magnitude of Cancer Risk

People with AT have a 100- to 1,000-fold elevated risk of developing lymphoma or leukemia compared to the general population. The most common malignancies are:

The cumulative cancer risk by age 20 is approximately 10%. Over a lifetime, roughly 30% of AT patients will develop a malignancy. Solid tumors also occur at higher rates, including breast cancer (relevant for adult survivors and for carriers — discussed below), brain tumors, and gastrointestinal cancers. Chromosomal instability in AT is particularly pronounced at the sites of the T-cell receptor genes on chromosomes 7 and 14, explaining the predominance of T-cell malignancies.

Radiation Hypersensitivity: A Critical Safety Issue

Radiation — whether diagnostic X-rays, CT scans, or therapeutic radiation — causes DNA double-strand breaks as its primary mechanism of biological effect. In healthy cells, ATM immediately senses these breaks and coordinates repair. In AT cells, this repair does not happen. The result is that AT patients are exquisitely sensitive to ionizing radiation at doses that would be entirely safe for other people.

This has direct and urgent implications for medical care:

Back to Table of Contents

Alpha-Fetoprotein and Diagnosis

One of the most practical and accessible diagnostic clues in AT is a simple blood test: serum alpha-fetoprotein (AFP). AFP is a protein normally produced by the fetal liver and yolk sac; levels are high at birth and fall to adult-normal values (below 10 ng/mL) by about 12 months of age. In AT patients, AFP levels remain persistently elevated beyond infancy and stay high throughout life — typically in the range of 10–2,000 ng/mL.

AFP as a Hallmark Biomarker

Elevated AFP is found in approximately 95% of AT patients, making it one of the most sensitive biomarkers for the condition. The exact mechanism for persistent AFP elevation in AT is not fully understood, but it is thought to reflect ongoing hepatocellular stress or abnormal liver regeneration related to ATM dysfunction in liver cells.

The combination of elevated AFP + low or absent IgA + progressive ataxia beginning in early childhood is a strong diagnostic signal. When a physician sees a young child with ataxia and measures AFP as part of the workup, finding a markedly elevated level should immediately prompt further AT-specific evaluation.

Full Diagnostic Workup

A complete diagnostic evaluation for AT includes:

There is no single definitive test; the diagnosis rests on the clinical picture combined with several supporting laboratory findings. Early genetic diagnosis allows appropriate management to begin sooner and protects the patient from radiation exposures that might otherwise occur during the diagnostic workup itself.

Back to Table of Contents

Treatment and Supportive Care

There is currently no disease-modifying therapy for AT that halts or reverses the underlying ATM dysfunction. Research into potential therapies — including read-through drugs for nonsense mutations, ATM activators, and gene therapy approaches — is active but has not yet produced clinical treatments. Management is therefore entirely supportive, aimed at preventing complications, treating infections aggressively, and maintaining function and quality of life as long as possible.

Immunoglobulin Replacement

For AT patients with documented humoral immunodeficiency and recurrent sinopulmonary infections, immunoglobulin replacement therapy (either IVIG given every 3–4 weeks or SCIG given weekly at home) replaces the IgG antibodies the patient's B cells cannot reliably produce. The goal is to maintain IgG trough levels above 5–7 g/L, reducing the frequency and severity of bacterial infections. Not every AT patient requires immunoglobulin replacement — it is reserved for those who have demonstrated deficient antibody levels plus significant infectious morbidity.

Infection Prevention and Treatment

Antibiotic prophylaxis — typically with trimethoprim-sulfamethoxazole (TMP-SMX) — is used in patients with recurrent bacterial infections to reduce the frequency of sinopulmonary episodes. When infections do occur, aggressive antibiotic treatment is essential to prevent the cumulative lung damage that leads to bronchiectasis. Prompt evaluation of any new respiratory symptoms, rather than watchful waiting, is strongly recommended.

Pulmonary Care

Preserving lung function is a priority. Annual spirometry (lung function testing) tracks respiratory decline. Chest physiotherapy — techniques to help clear mucus from the airways — is taught to patients and families and should be performed regularly. Bronchodilators (inhalers) help open constricted airways. Once bronchiectasis is established, an airway clearance device (such as an oscillating positive expiratory pressure device) may be added to the daily routine. Avoiding cigarette smoke exposure is important.

Neurological and Rehabilitation Support

Physical therapy (PT) helps maintain strength, balance, and mobility for as long as possible and guides the transition to adaptive equipment. Occupational therapy (OT) assists with adaptations for daily living — modified utensils, communication aids, and environmental modifications that support independence. Speech therapy addresses dysarthria and, if swallowing difficulties develop, helps prevent aspiration. When walking becomes unsafe, the transition to a powered wheelchair preserves independence and reduces injury risk from falls.

Radiation Avoidance — A Daily Priority

Every AT patient should carry a medical alert card explaining their diagnosis and stating that ionizing radiation (including CT scans and X-ray-based imaging) must be avoided whenever possible. This information must be proactively communicated to every doctor, nurse, and radiologist involved in care — including emergency and urgent care providers who may not know the patient. If imaging is unavoidable in an emergency, plain X-ray is preferable to CT; MRI and ultrasound are always preferred when clinically feasible.

Cancer Treatment When Malignancy Develops

When a cancer develops in an AT patient, treatment requires close collaboration between oncologists experienced in AT and the patient's primary care team. Standard chemotherapy protocols must be modified — DNA-damaging agents (alkylators, anthracyclines, topoisomerase inhibitors) should be dose-reduced by 25–50%. Standard radiotherapy doses are contraindicated; reduced-dose radiation or radiation avoidance must be planned. Hematopoietic stem cell transplantation (HSCT) is an option for certain leukemias and should be discussed with a center experienced in AT. Immune checkpoint inhibitors have been used in some AT malignancies and warrant evaluation.

Cancer Surveillance

Given the high cancer risk, AT patients should receive systematic cancer surveillance: annual physical examination with lymph node evaluation, low-threshold investigation of lymphadenopathy, baseline and periodic CBC to detect cytopenias suggesting marrow infiltration, and clinical evaluation of any unexplained constitutional symptoms (fever, night sweats, weight loss). Abdominal ultrasound can detect splenomegaly. The goal is early detection, when treatment options are broader.

Back to Table of Contents

Heterozygous ATM Carriers: Family Risk

Because AT is autosomal recessive, every person with AT has two parents who are obligate heterozygous ATM carriers — they carry one normal ATM gene and one defective copy. Siblings of an AT patient each have a 50% chance of being a carrier. With an estimated carrier frequency of approximately 1% of the general population, heterozygous ATM variants are among the most common disease-relevant gene variants in humans.

Carriers Do Not Have AT

Heterozygous carriers — one working copy of ATM — have enough ATM protein to function essentially normally. They do not develop the neurological, immune, or childhood-onset features of AT. A carrier who does not have a child with AT may never know they carry the mutation.

Elevated Cancer Risk in Carriers

However, carriers are not entirely unaffected. Research has established that heterozygous ATM mutation carriers have an elevated risk of breast cancer — approximately 2- to 3-fold compared to the general population. This places ATM carriers in an intermediate risk category, below the very high risk of BRCA1/2 mutation carriers but meaningfully above population baseline. The mechanism is the reduced ATM protein level in carrier cells, which impairs (but does not eliminate) DNA double-strand break repair capacity in the breast epithelium.

Recommendations for ATM carriers typically include:

Carrier Testing and Counseling

ATM gene sequencing is available and can identify carriers in families where the specific AT mutations are known. For families who have had an AT-affected child, carrier testing of parents and adult siblings is strongly recommended. Prenatal testing in future pregnancies is possible by chorionic villus sampling or amniocentesis once both parental mutations are identified.

Back to Table of Contents

Living with AT: Practical Guidance

Raising a child with AT, or living with AT as a young adult, involves navigating a healthcare system that often has limited familiarity with the condition, while managing the physical realities of progressive disability alongside the emotional weight of a serious multi-system disease. Several practical points can make a meaningful difference in day-to-day quality of life.

Communicating with the Medical Team

The most dangerous single scenario for an AT patient in a healthcare encounter is an uninformed clinician ordering a CT scan or administering standard-dose chemotherapy. Every visit to a doctor, emergency room, or specialist is an opportunity for miscommunication. Families should maintain an up-to-date one-page medical summary that lists the AT diagnosis, the most critical management rules (no CT scans, modified chemo protocols, no live vaccines), current medications, and contact information for the patient's immunologist and neurologist. This document should travel with the patient to every medical appointment.

School and Education

Children with AT have normal intelligence but progressive physical disability. An Individualized Education Plan (IEP) or 504 accommodation plan should be established early, addressing mobility aids (wheelchair access, elevator access), extended time for written work (coordination problems slow handwriting), speech assistance (dysarthria), and accommodations for fatigue. Voice-to-text software and tablet devices that reduce reliance on fine motor skills can significantly expand what a child with AT can accomplish academically.

Emotional and Psychological Support

AT does not impair intellect, which means children and young adults with AT fully understand what is happening to their bodies. The emotional burden — awareness of progressive disability, limited life expectancy, cancer risk — is real and significant. Mental health support, whether through a therapist familiar with chronic illness, peer support from other AT families, or family counseling, is as important as any medical intervention.

A-T Children's Project and Patient Organizations

The A-T Children's Project and the National Ataxia Foundation provide family support networks, research funding information, physician referral assistance, and educational materials specific to AT. Connecting with these organizations early — at the time of diagnosis — gives families access to a community with hard-won practical knowledge and a pipeline to emerging research.

Research and Clinical Trials

Active research areas in AT include read-through drugs (which allow ribosomes to skip premature stop codons, relevant for the ~30% of AT mutations that are nonsense variants), small-molecule ATM activators, gene therapy approaches, and novel cancer treatment protocols adapted to the AT context. Families should ask their treating team about eligibility for clinical trials and check ClinicalTrials.gov for AT-specific studies.

Back to Table of Contents

Key Research Papers

  1. Savitsky K et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995. PMID 7489349
  2. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol. 1997. PMID 9143705
  3. Taylor AM et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature. 1975. PMID 1059586
  4. Gatti RA et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature. 1988. PMID 3199430
  5. Boder E, Sedgwick RP. Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. Pediatrics. 1958. PMID 13543606
  6. Perlman S et al. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003. PMID 12915808
  7. Morrell D, Cromartie E, Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst. 1986. PMID 3515440
  8. Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2012. PMID 22586184
  9. Renault AL et al. ATM heterozygosity and breast cancer risk. J Natl Cancer Inst. 2016. PMID 27440219
  10. Rothblum-Oviedo L et al. Alpha-fetoprotein as a biomarker in ataxia-telangiectasia. J Child Neurol. 2004. PMID 15153151
  11. van Os NJH et al. Health outcomes of ataxia-telangiectasia patients in relation to ATM genotype. J Med Genet. 2017. PMID 28258194
  12. Staples ER et al. Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene. Clin Exp Immunol. 2008. PMID 18537944

Search PubMed for more: Ataxia-Telangiectasia on PubMed

Back to Table of Contents

Connections

Back to Table of Contents